Abstract
Neuroblastoma is a solid tumour that arises from the developing sympathetic nervous system. Over the past decade, our understanding of this disease has advanced tremendously. The future challenge is to apply the knowledge gained to developing risk-based therapies and, ultimately, improving outcome. In this Review we discuss the key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma, as well as new translational tools for bringing these promising scientific advances into the clinic.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Animals
-
Cancer Vaccines
-
DNA Helicases / genetics
-
Genomics
-
Humans
-
Immunotherapy*
-
Mutation
-
Neural Crest / pathology
-
Neuroblastoma / genetics*
-
Neuroblastoma / immunology
-
Neuroblastoma / therapy
-
Nuclear Proteins / genetics
-
Receptor Protein-Tyrosine Kinases / genetics
-
Sympathetic Nervous System / growth & development
-
Sympathetic Nervous System / pathology*
-
X-linked Nuclear Protein
Substances
-
Cancer Vaccines
-
Nuclear Proteins
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases
-
DNA Helicases
-
ATRX protein, human
-
X-linked Nuclear Protein